Sponsors: []Modifications: ; and(g)  if an applicant engages in compounding, submit the most recent inspection report:(i)  conducted within two years before the application for licensure; and(ii) (A)  conducted as part of the National Association of Boards of Pharmacy VerifiedPharmacy Program; or(B)  performed by the state licensing agency of the state in which the applicant is aresident and in accordance with the National Association of Boards of Pharmacy multistateinspection blueprint program.(4)  As a prerequisite for renewal of a class D pharmacy license of a pharmacy thatengages in compounding, a licensee shall submit the most recent inspection report:(a)  conducted within two years before the application for renewal; and(b) (i)  conducted as part of the National Association of Boards of Pharmacy VerifiedPharmacy Program; or(ii)  performed by the state licensing agency of the state in which the applicant is aresident and in accordance with the National Association of Boards of Pharmacy multistateinspection blueprint program.(a)(i)(ii)(iii)(iv)(v)(vi)(vii)(viii)(b)  The requirements described in Subsections (5)(a)(i) through (vi) do not apply to alabel on the container of a drug that a health care provider administers to a patient at:(i)  a pharmaceutical administration facility; or(ii)  a hospital licensed under Title 26, Chapter 21, Health Care Facility Licensing andInspection Act.     58-17b-625.(1)  A pharmacist may, in accordance with this section, administer a drug described inSubsection (2).(2)  Notwithstanding the provisions of Subsection 58-17b-102(57)(c)(ii)(B), thedivision shall make rules, in accordance with Title 63G, Chapter 3, Utah AdministrativeRulemaking Act, establishing training for a pharmacist to administer the following long-actinginjectables intramuscularly:(a)  aripiprazole;(b)  paliperidone;(c)  risperidone;(d)  olanzapine;(e)  naltrexone;(f)  naloxone; and(g)  drugs approved and regulated by the United States Food and Drug Administrationfor the treatment of the Human Immunodeficiency Virus.(3)  A pharmacist may not administer a drug listed under Subsection (2) unless thepharmacist:(a)  completes the training described in Subsection (2);(b)  administers the drug at a clinic or community pharmacy, as those terms are definedby the division, by administrative rule made in accordance with Title 63G, Chapter 3, UtahAdministrative Rulemaking Act; and(c)  is directed by the physician, as that term is defined in Section 58-67-102 or Section58-68-102, who issues the prescription to administer the drug.(1)  Except as provided in Subsection (2), this bill takes effect on May 9, 2017.(2)  The amendments to Sections 58-17b-306 and 58-17b-308 take effect on October 1,2017.Full text:



1     PHARMACY PRACTICE ACT AMENDMENTS2     2017 GENERAL SESSION3     STATE OF UTAH4     Chief Sponsor:  Evan J. Vickers5     House Sponsor:  Paul  Ray6      7     LONG TITLE8     General Description:9          This bill amends the Pharmacy Practice Act.10     Highlighted Provisions:11          This bill:12                requires certain Utah-licensed nonresident pharmacies to submit to an inspection as13     a prerequisite for licensure;14                excludes drugs administered under certain conditions from certain drug-container15     labeling requirements;16                permits certain pharmacists to administer long-acting injectable drugs17     intramuscularly under certain conditions; and18                makes technical changes.19     Money Appropriated in this Bill:20          None21     Other Special Clauses:22          This bill provides a special effective date.23     Utah Code Sections Affected:24     AMENDS:25          58-17b-306, as last amended by Laws of Utah 2009, Chapter 18326          58-17b-308, as last amended by Laws of Utah 2015, Chapter 25827          58-17b-602, as last amended by Laws of Utah 2014, Chapter 7228     ENACTS:29          58-17b-625, Utah Code Annotated 195330      31     Be it enacted by the Legislature of the state of Utah:32          Section 1.  Section 58-17b-306 is amended to read:33          58-17b-306. Qualifications for licensure as a pharmacy.34          (1)  Each applicant for licensure under this section, except for those applying for a class35     D license, shall:36          (a)  submit a written application in the form prescribed by the division;37          (b)  pay a fee as determined by the department under Section 63J-1-504;38          (c)  satisfy the division that the applicant, and each owner, officer, or manager of the39     applicant have not engaged in any act, practice, or omission, which when considered with the40     duties and responsibilities of a licensee under this section indicates there is cause to believe41     that issuing a license to the applicant is inconsistent with the interest of the public's health,42     safety, or welfare;43          (d)  demonstrate the licensee's operations will be in accordance with all federal, state,44     and local laws relating to the type of activity engaged in by the licensee, including regulations45     of the Federal Drug Enforcement Administration and Food and Drug Administration;46          (e)  maintain operating standards established by division rule made in collaboration47     with the board; and48          (f)  acknowledge the division's authority to inspect the licensee's business premises49     pursuant to Section 58-17b-103.50          (2)  Each applicant applying for a class D license shall:51          (a)  submit a written application in the form prescribed by the division;52          (b)  pay a fee as determined by the department under Section 63J-1-504;53          (c)  present to the division verification of licensure in the state where physically located54     and verification that such license is in good standing;55          (d)  provide a statement of the scope of pharmacy services that will be provided and a56     detailed description of the protocol as described by rule by which pharmacy care will be57     provided, including any collaborative practice arrangements with other health care58     practitioners;59          (e)  sign an affidavit attesting that any healthcare practitioners employed by the60     applicant and physically located in Utah have the appropriate license issued by the division and61     in good standing; [and]62          (f)  sign an affidavit attesting that the applicant will abide by the pharmacy laws and63     regulations of the jurisdiction in which the pharmacy is located[.]; and64          (g)  if an applicant engages in compounding, submit the most recent inspection report:65          (i)  conducted within two years before the application for licensure; and66          (ii) (A)  conducted as part of the National Association of Boards of Pharmacy Verified67     Pharmacy Program; or68          (B)  performed by the state licensing agency of the state in which the applicant is a69     resident and in accordance with the National Association of Boards of Pharmacy multistate70     inspection blueprint program.71          (3)  Each license issued under this section shall be issued for a single, specific address,72     and is not transferable or assignable.73          Section 2.  Section 58-17b-308 is amended to read:74          58-17b-308. Term of license -- Expiration -- Renewal.75          (1)  Except as provided in Subsection (2), each license issued under this chapter shall be76     issued in accordance with a two-year renewal cycle established by rule.  A renewal period may77     be extended or shortened by as much as one year to maintain established renewal cycles or to78     change an established renewal cycle.  Each license automatically expires on the expiration date79     shown on the license unless renewed by the licensee in accordance with Section 58-1-308.80          (2)  The duration of a pharmacy intern license may be no longer than:81          (a)  one year for a license issued under Subsection 58-17b-304(7)(b); or82          (b)  five years for a license issued under Subsection 58-17b-304(7)(a).83          (3)  A pharmacy intern license issued under this chapter may not be renewed, but may84     be extended by the division in collaboration with the board.85          (4)  As a prerequisite for renewal of a class D pharmacy license of a pharmacy that86     engages in compounding, a licensee shall submit the most recent inspection report:87          (a)  conducted within two years before the application for renewal; and88          (b) (i)  conducted as part of the National Association of Boards of Pharmacy Verified89     Pharmacy Program; or90          (ii)  performed by the state licensing agency of the state in which the applicant is a91     resident and in accordance with the National Association of Boards of Pharmacy multistate92     inspection blueprint program.93          Section 3.  Section 58-17b-602 is amended to read:94          58-17b-602. Prescription orders -- Information required -- Alteration -- Labels --95     Signatures -- Dispensing in pharmacies.96          (1)  Except as provided in Section 58-1-501.3, the minimum information that shall be97     included in a prescription order, and that may be defined by rule, is:98          (a)  the prescriber's name, address, and telephone number, and, if the order is for a99     controlled substance, the patient's age and the prescriber's DEA number;100          (b)  the patient's name and address or, in the case of an animal, the name of the owner101     and species of the animal;102          (c)  the date of issuance;103          (d)  the name of the medication or device prescribed and dispensing instructions, if104     necessary;105          (e)  the directions, if appropriate, for the use of the prescription by the patient or animal106     and any refill, special labeling, or other instructions;107          (f)  the prescriber's signature if the prescription order is written;108          (g)  if the order is an electronically transmitted prescription order, the prescribing109     practitioner's electronic signature; and110          (h)  if the order is a hard copy prescription order generated from electronic media, the111     prescribing practitioner's electronic or manual signature.112          (2)  The requirement of Subsection (1)(a) does not apply to prescription orders113     dispensed for inpatients by hospital pharmacies if the prescriber is a current member of the114     hospital staff and the prescription order is on file in the patient's medical record.115          (3)  Unless it is for a Schedule II controlled substance, a prescription order may be116     dispensed by a pharmacist or pharmacy intern upon an oral prescription of a practitioner only if117     the oral prescription is promptly reduced to writing.118          (4) (a)  Except as provided under Subsection (4)(b), a pharmacist or pharmacy intern119     may not dispense or compound any prescription of a practitioner if the prescription shows120     evidence of alteration, erasure, or addition by any person other than the person writing the121     prescription.122          (b)  A pharmacist or pharmacy intern dispensing or compounding a prescription may123     alter or make additions to the prescription after receiving permission of the prescriber and may124     make entries or additions on the prescription required by law or necessitated in the125     compounding and dispensing procedures.126          (5) (a)  Each drug dispensed shall have a label securely affixed to the container127     indicating the following minimum information:128          [(a)] (i)  the name, address, and telephone number of the pharmacy;129          [(b)] (ii)  the serial number of the prescription as assigned by the dispensing pharmacy;130          [(c)] (iii)  the filling date of the prescription or its last dispensing date;131          [(d)] (iv)  the name of the patient, or in the case of an animal, the name of the owner132     and species of the animal;133          [(e)] (v)  the name of the prescriber;134          [(f)] (vi)  the directions for use and cautionary statements, if any, which are contained in135     the prescription order or are needed;136          [(g)] (vii)  except as provided in Subsection (7), the trade, generic, or chemical name,137     amount dispensed and the strength of dosage form, but if multiple ingredient products with138     established proprietary or nonproprietary names are prescribed, those products' names may be139     used; and140          [(h)] (viii)  the beyond use date.141          (b)  The requirements described in Subsections (5)(a)(i) through (vi) do not apply to a142     label on the container of a drug that a health care provider administers to a patient at:143          (i)  a pharmaceutical administration facility; or144          (ii)  a hospital licensed under Title 26, Chapter 21, Health Care Facility Licensing and145     Inspection Act.146          (6)  A hospital pharmacy that dispenses a prescription drug that is packaged in a147     multidose container to a hospital patient may provide the drug in the multidose container to the148     patient when the patient is discharged from the hospital if:149          (a)  the pharmacy receives a discharge order for the patient; and150          (b)  the pharmacy labels the drug with the:151          (i)  patient's name;152          (ii)  drug's name and strength;153          (iii)  directions for use of the drug, if applicable; and154          (iv)  pharmacy's name and phone number.155          (7)  If the prescriber specifically indicates the name of the prescription product should156     not appear on the label, then any of the trade, generic, chemical, established proprietary, and157     established nonproprietary names and the strength of dosage form may not be included.158          (8)  Prescribers are encouraged to include on prescription labels the information159     described in Section 58-17b-602.5 in accordance with the provisions of that section.160          (9)  A pharmacy may only deliver a prescription drug to a patient or a patient's agent:161          (a)  in person at the pharmacy; or162          (b)  via the United States Postal Service, a licensed common carrier, or supportive163     personnel, if the pharmacy takes reasonable precautions to ensure the prescription drug is:164          (i)  delivered to the patient or patient's agent; or165          (ii)  returned to the pharmacy.166          Section 4.  Section 58-17b-625 is enacted to read:167          58-17b-625. Administration of a long-acting injectable drug therapy.168          (1)  A pharmacist may, in accordance with this section, administer a drug described in169     Subsection (2).170          (2)  Notwithstanding the provisions of Subsection 58-17b-102(57)(c)(ii)(B), the171     division shall make rules, in accordance with Title 63G, Chapter 3, Utah Administrative172     Rulemaking Act, establishing training for a pharmacist to administer the following long-acting173     injectables intramuscularly:174          (a)  aripiprazole;175          (b)  paliperidone;176          (c)  risperidone;177          (d)  olanzapine;178          (e)  naltrexone;179          (f)  naloxone; and180          (g)  drugs approved and regulated by the United States Food and Drug Administration181     for the treatment of the Human Immunodeficiency Virus.182          (3)  A pharmacist may not administer a drug listed under Subsection (2) unless the183     pharmacist:184          (a)  completes the training described in Subsection (2);185          (b)  administers the drug at a clinic or community pharmacy, as those terms are defined186     by the division, by administrative rule made in accordance with Title 63G, Chapter 3, Utah187     Administrative Rulemaking Act; and188          (c)  is directed by the physician, as that term is defined in Section 58-67-102 or Section189     58-68-102, who issues the prescription to administer the drug.190          Section 5.  Effective date.191          (1)  Except as provided in Subsection (2), this bill takes effect on May 9, 2017.192          (2)  The amendments to Sections 58-17b-306 and 58-17b-308 take effect on October 1,193     2017.

